Nitromint (Glyceryl Trinitrate)

Glyceryl trinitrate is metabolized to nitric oxide in vascular smooth muscle. Nitric oxide activates soluble guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP). Elevated cGMP causes relaxation of smooth muscle, producing venous and arterial dilation, reducing preload and afterload, and lowering myocardial oxygen demand, which alleviates ischemic chest pain.

The specific dose of Nitromint is individualized by the prescribing clinician. Dosage may be adjusted according to the severity of angina, patient tolerance, and response to therapy. Patients should follow the exact regimen provided on the prescription label and consult their healthcare provider for any adjustments.

The safety of glyceryl trinitrate in pregnancy and lactation has not been definitively established, and it is generally classified as a category where risk cannot be ruled out. Healthcare providers will weigh potential benefits against possible risks before prescribing to pregnant or nursing individuals. Use only if clearly indicated.

To request Nitromint, visit the product page on gnhindia.com, enter the desired quantity, and submit the inquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any required import documentation.

Nitromint (glyceryl trinitrate) belongs to the nitrate class, providing rapid vasodilation and relief of acute chest pain, whereas beta‑blockers reduce heart rate and contractility, and calcium‑channel blockers primarily affect arterial tone. Nitrates are often used for immediate symptom control, while other agents are used for long‑term prevention; choice depends on clinical context.

Nitromint should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or extreme temperatures, which could affect its stability and efficacy.

Nitromint is taken orally as directed by a healthcare professional. The tablet (or sublingual form if applicable) is placed under the tongue or swallowed, depending on the specific product formulation and the prescriber's instructions. Administration should occur on an empty stomach for optimal absorption, and patients should avoid crushing or chewing unless advised.

The most serious adverse reactions to Nitromint include severe hypotension, syncope, and rare cases of myocardial infarction or methemoglobinemia. Patients should be monitored for sudden drops in blood pressure, dizziness, or chest discomfort, and seek immediate medical attention if these symptoms occur. Prompt reporting of any severe side effects is essential.

Nitromint is contraindicated in individuals with known hypersensitivity to glyceryl trinitrate or other nitrates, patients who have taken phosphodiesterase‑5 inhibitors (e.g., sildenafil) within the past 24–48 hours, and those with severe anemia, increased intracranial pressure, or uncompensated heart failure. Clinicians must assess each patient’s medical history before prescribing.